Adma Biologics, Inc 8-K, filed Mar 10, 2023
Adma Biologics, Inc. (ADMA)
8-K
2023-03-10
For: 2023-03-06
View Original
Added on
April 04, 2026
About this 8-K
Adma Biologics, Inc filed this 8-K on March 10, 2023, reporting on events of March 6, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2023
|
(Exact name of registrant as specified in its charter)
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (201 ) 478-5552
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Executive Compensation
On March 6, 2023, upon the recommendation of the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of ADMA Biologics, Inc.
(the “Company”), the Board approved the following base salaries for 2023, cash bonuses attributable to 2022 performance and annual incentive awards for the Company’s named executive officers, as set forth below:
|
Name
|
Position
|
2023 Base Salary
|
2022 Non-Equity Incentive Compensation (1)
|
Number of
RSUs (2)(3)
|
Number of Shares
Underlying Stock
Options (2)(4)(5)
|
||||||||||||
|
Adam S. Grossman
|
President, Chief Executive
Officer and Director
|
$
|
750,000
|
$
|
612,351
|
573,695
|
1,147,385
|
||||||||||
|
Brian Lenz
|
Executive Vice President, Chief Financial Officer
|
$
|
475,000
|
$
|
296,755
|
135,175
|
270,345
|
||||||||||
| (1) |
Amounts reflect a cash bonus that will be paid by the Company to the named executive officers pursuant to such officer’s employment agreement. These cash bonus amounts reflect
achievement of 148% of the Company’s 2022 corporate goals and milestones.
|
| (2) |
Grant date was March 6, 2023.
|
| (3) |
The Restricted Stock Units (“RSUs”) will vest quarterly on each anniversary of the date of grant (over four years) in accordance with the ADMA Biologics, Inc. 2022 Equity
Compensation Plan (the “Plan”).
|
| (4) |
The stock options’ exercise price of $3.35 reflects the per share fair market value of the Company’s common stock, $0.0001 par value per share (“Common Stock”), as determined by
the closing price of the Company’s Common Stock on the Nasdaq Global Market on the grant date.
|
| (5) |
The stock options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining
75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027 in accordance with the Plan.
|
The Compensation Committee reached its recommendation regarding the compensation and incentive awards for the named executive officers in consultation with an independent
compensation consultant. The non-equity incentive compensation, RSUs, and stock options were awarded at the discretion of the Compensation Committee and were based on each named executive officer’s annual cash bonus and equity targets, as
established by the Compensation Committee, and the Compensation Committee’s evaluation of the performance including the non-equity incentive compensation of each named executive officer, all of which have been approved by the Board.
Director Compensation
On March 6, 2023, upon the recommendation of the Compensation Committee, the Board approved an updated non‑employee director compensation policy, effective and
retroactive to January 1, 2023. Pursuant to the updated non-employee director compensation policy, each non-employee director of the Company will be paid an annual cash retainer of $50,000. The Chairman and Vice-Chairman will each be paid an
additional fee of $40,000. The Chairman of the Audit Committee, the Chairman of the Compensation Committee and the Chairman of the Governance and Nominations Committee will each be paid $22,250, $16,500 and $11,000, respectively. Members of the
Audit Committee, the Compensation Committee and the Governance and Nominations Committee will each be paid a retainer of $11,125, $8,250 and $5,500, respectively. Furthermore, new directors will receive an initial equity grant award with a value of
$350,000, delivered as options.
| Item 9.01 |
Exhibits
|
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
104
|
Cover Page Interactive Data File (embedded with the Inline XBRL Document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
March 10, 2023
|
ADMA Biologics, Inc.
|
||
|
By:
|
/s/ Brian Lenz
|
||
|
Name:
|
Brian Lenz
|
||
|
Title:
|
Executive Vice President and Chief Financial Officer
|
||